Latest Breaking News On - ஆய்வகம் ஆஃப் வைராலஜி - Page 5 : comparemela.com

MK-4482 shows potential to prevent and treat SARS-CoV-2 infection. This scanning electron microscope image shows SARS-CoV-2 (orange) also known as 2019-nCoV, the virus that causes COVID-19 isolated from a patient in the U.S., emerging from the surface of cells (gray) cultured in the lab. NIAID What The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists. SARS-CoV-2 is the virus that causes COVID-19. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings.

Rocky mountainUnited statesUnited kingdomHeinz feldmannKyle rosenkeRidgeback biotherapeuticsMichaela jarvisNature communicationsNational institute of allergyUs department of healthHuman servicesNational institutes of healthDrug administrationLaboratory of virologyUniversity of plymouthEmory university drug innovation ventures